A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Bio N Tech Se stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 2,857 shares of BNTX stock, worth $323,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,857
Previous 3,127 8.63%
Holding current value
$323,069
Previous $251,000 35.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$78.36 - $124.66 $21,157 - $33,658
-270 Reduced 8.63%
2,857 $339,000
Q2 2024

Aug 12, 2024

BUY
$80.36 - $102.87 $60,189 - $77,049
749 Added 31.5%
3,127 $251,000
Q1 2024

May 09, 2024

SELL
$88.96 - $112.35 $9,696 - $12,246
-109 Reduced 4.38%
2,378 $219,000
Q4 2023

Feb 08, 2024

SELL
$90.91 - $112.75 $21,636 - $26,834
-238 Reduced 8.73%
2,487 $262,000
Q3 2023

Nov 07, 2023

BUY
$98.5 - $125.08 $27,481 - $34,897
279 Added 11.41%
2,725 $296,000
Q2 2023

Aug 09, 2023

BUY
$102.58 - $129.66 $84,218 - $106,450
821 Added 50.52%
2,446 $263,000
Q1 2023

May 08, 2023

BUY
$122.57 - $153.67 $13,972 - $17,518
114 Added 7.54%
1,625 $202,000
Q4 2022

Feb 07, 2023

BUY
$118.43 - $186.05 $2,960 - $4,651
25 Added 1.68%
1,511 $226,000
Q3 2022

Nov 01, 2022

SELL
$127.65 - $183.11 $1,659 - $2,380
-13 Reduced 0.87%
1,486 $200,000
Q2 2022

Aug 04, 2022

BUY
$123.25 - $186.24 $51,148 - $77,289
415 Added 38.28%
1,499 $224,000
Q4 2021

Feb 07, 2022

SELL
$216.64 - $362.52 $97,054 - $162,408
-448 Reduced 29.24%
1,084 $251,000
Q2 2021

Aug 06, 2021

BUY
$113.32 - $241.49 $173,606 - $369,962
1,532 New
1,532 $343,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.